- Home
- AIRJ vs FHTX Comparison
AIRJ vs FHTX Comparison
Compare AIRJ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- FHTX
- Stock Information
- Founded
- AIRJ 2018
- FHTX 2015
- Country
- AIRJ United States
- FHTX United States
- Employees
- AIRJ N/A
- FHTX N/A
- Industry
- AIRJ
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- AIRJ
- FHTX Health Care
- Exchange
- AIRJ NYSE
- FHTX Nasdaq
- Market Cap
- AIRJ 278.3M
- FHTX 271.5M
- IPO Year
- AIRJ N/A
- FHTX 2020
- Fundamental
- Price
- AIRJ $3.98
- FHTX $4.99
- Analyst Decision
- AIRJ Strong Buy
- FHTX Strong Buy
- Analyst Count
- AIRJ 1
- FHTX 8
- Target Price
- AIRJ $12.00
- FHTX $12.63
- AVG Volume (30 Days)
- AIRJ 108.0K
- FHTX 121.4K
- Earning Date
- AIRJ 08-22-2025
- FHTX 08-07-2025
- Dividend Yield
- AIRJ N/A
- FHTX N/A
- EPS Growth
- AIRJ N/A
- FHTX N/A
- EPS
- AIRJ 0.86
- FHTX N/A
- Revenue
- AIRJ N/A
- FHTX $23,504,000.00
- Revenue This Year
- AIRJ N/A
- FHTX $33.60
- Revenue Next Year
- AIRJ N/A
- FHTX $5.87
- P/E Ratio
- AIRJ $4.78
- FHTX N/A
- Revenue Growth
- AIRJ N/A
- FHTX N/A
- 52 Week Low
- AIRJ $3.74
- FHTX $2.95
- 52 Week High
- AIRJ $11.60
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- AIRJ 37.92
- FHTX 40.37
- Support Level
- AIRJ $4.36
- FHTX $6.00
- Resistance Level
- AIRJ $4.99
- FHTX $6.79
- Average True Range (ATR)
- AIRJ 0.31
- FHTX 0.42
- MACD
- AIRJ -0.08
- FHTX -0.16
- Stochastic Oscillator
- AIRJ 4.72
- FHTX 3.37
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.